Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Savient Pharmaceuticals Stories

2014-01-10 08:23:06

Acquisition is highlighted by KRYSTEXXA® (pegloticase), the only product approved for the treatment of refractory chronic gout GLENDALE, Wis., Jan. 10, 2014 /PRNewswire/ -- Crealta Pharmaceuticals LLC ("Crealta"), a new specialty pharmaceutical company, announced today the completion of the acquisition of substantially all of the assets of Savient Pharmaceuticals, Inc. ("Savient"). Crealta previously announced the winning of an auction for these assets, the signing of a definitive...

2013-12-13 12:23:52

BRIDGEWATER, N.J. and GLENDALE, Wis., Dec. 13, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (OTC: SVNTQ) ("Savient") announced today that it has received approval from the U.S. Bankruptcy Court for the District of Delaware (the "Court") to sell substantially all of the assets of Savient, including all KRYSTEXXA® assets, to Crealta Pharmaceuticals LLC ("Crealta"). As previously announced, Savient and Crealta have entered into an acquisition agreement through which Crealta...

2013-12-11 08:29:33

- KRYSTEXXA® (pegloticase), the only product approved for refractory chronic gout, included in the sale. BRIDGEWATER, N.J. and GLENDALE, Wis., Dec. 11, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds...

2013-12-10 00:22:02

Savient to Seek Court Approval of Final Cash Collateral Order on December 13, 2013 BRIDGEWATER, N.J., Dec. 10, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that an agreement in principle has been reached by and among Savient, the Official Committee of Unsecured Creditors appointed in Savient's Chapter 11 case (the "UCC") and the Unofficial Committee of Senior Secured Noteholders (the "Unofficial Committee" and, together with Savient and the...

2013-10-16 16:26:47

Court Grants Orders to Support Business Operations BRIDGEWATER, N.J., Oct. 16, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT)("Savient") announced today the approval of its "first day" motions by the U.S. Bankruptcy Court for the District of Delaware (the "Court") that will allow the Company's operations to continue uninterrupted through the Chapter 11 process. The Court approval allows the Company to conduct its business uninterrupted and continue to meet its...

2013-10-14 20:20:47

Enters into "Stalking Horse" Sale Agreement with US WorldMeds, LLC BRIDGEWATER, N.J., Oct. 14, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) ("Savient") announced today that it has elected to file voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the "Court"). Savient also filed a motion seeking authorization to pursue a sale process under Section 363 of the U.S. Bankruptcy Code. To this...

2013-10-08 08:29:38

BRIDGEWATER, N.J., Oct. 8, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that an abstract related to KRYSTEXXA(®) (pegloticase) has been selected for poster presentation at the American Society of Nephrology (ASN) Kidney Week 2013. The annual meeting will be held November 5-10, 2013, in Atlanta, GA. Savient's abstract, #FR-PO417, entitled "Pegloticase, a Recombinant Uricase for the Treatment of Advanced Gout, Maintains Therapeutic...

2013-10-03 16:23:32

BRIDGEWATER, N.J., Oct. 3, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that several abstracts related to KRYSTEXXA(®) (pegloticase) have been selected for presentation at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2013 Annual Meeting. The 2013 ACR/ARHP annual meeting will be held October 26-30, 2013, in San Diego, CA. Full text of the following accepted abstracts can be accessed by visiting the...

2013-06-20 16:27:31

BRIDGEWATER, N.J., June 20, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that it has formed an Office of the President, consisting of Richard Crowley, who will serve as Co-President and Chief Operating Officer, John P. Hamill, who will serve as Co-President and Chief Financial Officer, and Philip K. Yachmetz, who will serve as Co-President and Chief Business Officer. Savient also announced that Louis Ferrari, President, Chief Executive Officer, and...

2013-06-12 08:28:51

-- Post-Marketing Data Focuses on Safety of KRYSTEXXA® and the Appropriate Actions Taken From Post-Approval Safety Surveillance BRIDGEWATER, N.J., June 12, 2013 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that ongoing KRYSTEXXA(® )(pegloticase) post-marketing surveillance data describing the long-term safety data for KRYSTEXXA will be presented at the 2013 EULAR Congress in Madrid, Spain June 12-15. The two posters describe a decrease in the...